Therapies that utilize Blimp-1’s regulatory functions, with the goal of treating the oxidative stress, inflammation, and metabolic dysfunction that are at the root of disease progression in diabetes, cardiovascular disease, and autoimmune disorders, would unify these fields. This evidence concerns the gene PRDM1 and autoimmune disease.